If you have been reading about reversed-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | No marketing authorization in major jurisdictions |
| Scheduling example | Prescription-only supply in some countries | Handled as an unlicensed medicine where restricted |
| Sports classification | Prohibited peptide | Appears on anti-doping prohibited lists |
| Reported presentation | Lyophilized vial | Nominal content varies between vendors |
| Detection approach | Liquid chromatography–tandem mass spectrometry | Used in anti-doping and forensic testing |
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
During atrial systole, blood flows from the atria to the ventricles down the pressure gradient. Chordae tendineae are relaxed because the atrioventricular (AV) valves are forced open. When the ventricles of the heart contract in ventricular systole, the increased blood pressures in both chambers push the AV valves to close simultaneously, preventing the backflow of blood into the atria. Since the blood pressure in the atria is much lower than that in the ventricles, the flaps attempt to evert to the low pressure regions. The chordae tendineae prevent this prolapse by becoming tense, which pulls on the flaps, holding them in a closed position.
=== Medications === Some medications, such as glucocorticoids, cannabinoids, and progestins were initially used in treating cachexia and aim to increase appetite. Progestins showed promise initially, but they do not stop muscle wasting and may cause fluid retention, fat gain, and other side effects. Ghrelin agonists, such as anamorelin are commonly used in cancer treatment to boost appetite, increase weight, and increase muscle mass. However, its use and effectiveness in cachexia is not well studied. Selective androgen receptor modulators (SARMs) such as enobosarm show promise in increasing physical performance and muscle mass, but more studies are needed to confirm their effectiveness in cachexia. The use of anti-inflammatory medications have been investigated. Thalidomide, an anti-inflammatory agent, has shown promise in preventing weight loss, but the use of this medication in cachexia is not widely accepted. However, other TNF inhibitors have not shown the same promising results. NSAIDs such as celecoxib and ibuprofen showed some early benefits, but side effects (renal injury, GI bleeding) limit their use. Anti-nausea drugs such as 5-HT3 antagonists are also commonly used if nausea is a prominent symptom. Anabolic steroids like oxandrolone may help but are only recommended for short term use due to side effects including liver toxicity.
=== Pharmacodynamics === DOPR acts as an agonist of the serotonin 5-HT2 receptors, including of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. It has very weak affinity for the serotonin 5-HT1 receptor. The drug has also been assessed at other receptors. It produces the head-twitch response (HTR), a behavioral proxy of psychedelic effects, in rodents. It is slightly more potent but slightly less efficacious than DOM in producing the head-twitch response. As with many other psychedelics, DOPR shows an inverted U-shaped dose–response curve in terms of the HTR, increasing it at lower doses and having diminished effectiveness at higher doses. DOPR showed no significant effects on locomotor activity in rodents at the assessed doses, but showed a trend towards hyperlocomotion at the highest dose. In a subsequent study however, it produced hyperlocomotion at lower doses and hypolocomotion at higher doses. The drug has shown pro-motivational effects in rodents at sub-hallucinogenic doses or so-called "microdoses". DOPR's close analogue DOET has also been clinically studied at sub-hallucinogenic doses as a "psychic energizer". DOPR produces antidepressant-like effects in rodents. At higher doses, DOPR produces hypothermia in rodents.
Historically, it was used in folk medicine to treat jaundice and as a natural dye source for textiles. More recently, it has become a subject of astrobiology research, where it survives Mars-like environments, space vacuum, cosmic radiation, and extreme cold. This resilience has established X. parietina as a model organism in both environmental monitoring and space exploration research.
== Use in drug discovery == Understanding of the molecular basis of binding to integrins has enabled the development of several drugs for cardiovascular disease and cancer, including eptifibatide, tirofiban and cilengitide. These drugs inhibit integrin binding. PET radiotracers such as fluciclatide utilize RGD-containing peptides to home to tumors, allowing for cancer monitoring.
Sources: en.wikipedia.org
The northern and the western parts were reorganised as the Reichsgau Sudetenland, with the city of Reichenberg (present-day Liberec) established as its capital. Konrad Henlein (now openly an NSDAP member) administered the district first as Reichskommissar (until 1 May 1939) and then as Reichsstatthalter (1 May 1939 – 4 May 1945). The Sudetenland consisted of three administrative districts (Regierungsbezirke): Eger (with Karlsbad as capital), Aussig (Aussig) and Troppau (Troppau).
Billericay ( BIL-ə-RIK-ee) is a historic market town and civil parish in the Borough of Basildon, Essex, England. It lies 23 miles (37 km) east of the City of London. At the 2021 census, the parish had a population of 28,562 and the built-up area was 34,075. The town was founded in the 13th century by the Abbot of West Ham, in his Manor of Great Burstead. During the Peasants’ Revolt of 1381, the Essex rebels were defeated in a battle with Richard II's forces in the Battle of Billericay. In 1620, four local people were on board the Mayflower as it sailed to Massachusetts, to establish the first English settlement in what would become the north of the United States. The town has long taken a pride in this connection; many businesses and other organisations use the name Mayflower, with the town council and other local organisations using it as their emblem.
The goal of this process is to reduce the amount of material being transferred to the surface and minimize land-based. The dewatering process is a mining waste process that would most likely contribute to the formation of sediment plumes from the surface. The method of mine waste disposal releases water from the ship that may have been obtained during the extraction and transport of the material from the seafloor to the surface. The third contribution to the formation of the sediment plume or cloud would be sediment disturbance and release. This mining waste contribution is mainly associated with the mining activity on the seafloor associated with the movement of the ROVs and the destructive disturbance of the seafloor as part of the mining process itself. The two main environmental concerns as a result of these waste mining processes that contribute to the formation of the sediment plume would be the release of heavy metals and increased amounts of sediment released. The release of heavy metals is mainly associated with the dewatering process that would take place on board the ship at the surface of the water. The main problem associated with dewatering is that it is not just the release of seawater re-entering the water column. Heavy metals such as copper and cobalt that would be sourced from the material extracted on the seafloor are also mixed in with the water that is released into the water column. The first environmental concern associated with the release of heavy metals is that it has the potential to change ocean chemistry within that localized water column area.
As of this edit, this article uses content from "2.A.17 The Proton-dependent Oligopeptide Transporter (POT/PTR) Family", which is licensed in a way that permits reuse under the Creative Commons Attribution-ShareAlike 3.0 Unported License, but not under the GFDL. All relevant terms must be followed.
Mahathir was a prominent international advocate for Bosniaks in Bosnia and Herzegovina during his tenure. His government permitted Bosnians to come to Malaysia without a visa during the Bosnian War. He was influential in the establishment of an OIC summit in Karachi in 1993 to discuss the need for weapons for Bosnia during the War. Malaysia sent UN Peacekeeping forces to Bosnia and was part of the Contact Group advocating for Bosnia at the UN. In February 2007, Mahathir was nominated by four non-governmental organisations in Bosnia and Herzegovina for the Nobel Peace Prize that year. The nominations were made by the Serb Civic Council from Bosnia and Herzegovina, the Croat National Council, the Sarajevo School of Science and Technology, and the Congress of Bosnik Intellectuals.
Sources: en.wikipedia.org
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.
The peptide is listed as prohibited in competitive sport, so laboratories develop detection methods and monitor for its presence. Its appearance in enforcement reports reflects that classification rather than any approved athletic use. Analytical work in this area focuses on identifying the molecule and its breakdown products in biological samples.
Chromatographic separation combined with mass spectrometry identifies the peptide and estimates its amount in a sample. Testing can confirm whether the expected molecule is present and at what concentration. It cannot establish how a product was manufactured or whether it meets any purity standard.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.